ABSTRACT BOOK ABSTRACTS



A new ERA for global Dermatology 10 - 15 JUNE 2019 MILAN, ITALY

PSORIASIS

ACHIEVING AND MAINTAINING LONG-TERM OPTIMAL IMPROVEMENTS IN PATIENT-REPORTED SYMPTOMS, SIGNS, AND QUALITY OF LIFE AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH GUSELKUMAB: 3-YEAR DATA

A Blauvelt⁽¹⁾ - C Han⁽²⁾ - Ka Papp⁽³⁾ - Cem Griffiths⁽⁴⁾ - P Fernandez-penas⁽⁵⁾ - Dn Adam⁽⁶⁾ - S Philipp⁽⁷⁾ - M Song⁽⁸⁾ - Y-k Shen⁽⁹⁾ - Ab Kimball⁽¹⁰⁾

Oregon Medical Research Center, Dermatology, Portland, United States⁽¹⁾ - Janssen Research & Development, Llc, Clinical, Spring House, United States⁽²⁾ - K Papp Clinical Research And Probity Medical Research Inc., Dermatology, Waterloo, Canada⁽³⁾ -Dermatology Centre, Salford Royal Hospital, University Of Manchester, Dermatology, Manchester, United Kingdom⁽⁴⁾ - University Of Sydney And Westmead Hospital, Dermatology, Sydney, Australia⁽⁵⁾ - University Of Toronto And Probity Medical Research, Dermatology, Ajax, Canada⁽⁶⁾ - Dermatology, Charité, Universitaetsmedizin Berlin, Dermatology, Berlin, Germany⁽⁷⁾ - Janssen Research & Development, Llc, Immunology, Spring House, United States⁽⁸⁾ - Janssen Research & Development, Llc, Clinical Biostatistics, Spring House, United States⁽⁹⁾ - Harvard Medical School, Dermatology, Boston, United States⁽¹⁰⁾

Introduction/Objective: VOYAGE 1 is a Phase 3 trial of guselkumab (GUS) in pts with moderate-to-severe plaque psoriasis (PsO). This post-hoc analysis presents data through up to 3-years among pts treated with GUS.

Materials/Methods: Adults were randomized (2:1:2) to:GUS/PBO/ADA. The open-label phase began after Wk48; GUS and PBO/GUS pts continued to receive GUS 100mg q8w and ADA pts were switched to GUS 100mg q8w at Wk 52. Two PRO instruments were assessed: Psoriasis Symptom and Sign Diary (PSSD) and Dermatology Life Quality Index (DLQI). The PSSD captures 5 symptoms (itch, pain, stinging, burning, and skin tightness) and 6 pt-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using severity scale 0-10. A score of 0 for PSSD total symptoms or signs, or individual scale items was equated with symptom-free or sign-free status. DLQI, assesses 6 different aspects that may affect QoL; a score of 0 or 1 indicates no or minimal impact of PsO on HRQOL. For this analysis, data for all pts who received GUS in the open-label phase were combined; results from Wk76 to Wk156 were compared.

Results: Among 774 pts, symptom-free status was reported at Wks76-156 by 49.0%-50.0%







ABSTRACT BOOK ABSTRACTS



A new ERA for global Dermatology 10 - 15 JUNE 2019 MILAN, ITALY

for itch, 77.0%-75.5% pain, 76.9%74.7% stinging, 79.0%-76.0% burning, and 61.4%-59.5% skin tightness. Sign-free status was reported by 39.5%-40.8% for skin dryness, 72.6%-69.9% cracking, 53.0%-52.1% scaling, 56.4%-51.1% shedding or flaking, 54.5%-54.0% redness, and 87.7%-87.8% bleeding. From Wks76-156, 40.8% to 42.2% of pts reported no symptoms, and 30.1% to 34.2% reported no signs. About 75% of pts achieved and maintained a DLQI score of 0 or 1 from Wks76-156, indicating PsO had no or minimal impacts on their daily life.

Conclusions: GUS therapy through up to 3 years resulted in optimal improvements in ptreported symptoms, signs, and HRQOL for many pts w/moderate-severe PsO.



24TH WORLD CONGRESS OF DERMATOLOGY MILAN 2019



International League of Dermatological Societies Skin Health for the World

